Drug Safety Efficacy
Drug Safety Efficacy - Related Videos
02:48
Determining Antiviral Efficacy of Experimental Drugs Through a Plaque Assay
0 Views •
2025
This video demonstrates the method to perform a plaque assay using a virus obtained from infected porcine cornea. The porcine cornea is used to test the antiviral efficacy of experimental drugs.
05:14
An Assay to Evaluate Drug Efficacy against a Mycobacterium tuberculosis Infection Model
0 Views •
2025
This video demonstrates an assay to evaluate the efficacy of drugs against Mycobacterium tuberculosis (Mtb) infection. An in vitro infection model containing Mtb/macrophage aggregates is generated that mimics in vivo infection. Upon introducing suitable antibiotics, their efficacy is tested via resuzarin assay to monitor the survival of bacteria with increasing drug concentrations.
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
0 Views •
Cited by 1 •
2017
New models and assays that would improve the early drug development process for next-generation anti-tuberculosis drugs are highly desirable. Here, we describe a quick, inexpensive, and BSL-2 compatible assay to evaluate drug efficacy against Mycobacterium tuberculosis that can be easily adapted for high-throughput screening.
10:39
Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
0 Views •
Cited by 38 •
2017
Here, we show the generation of human engineered heart tissue from induced pluripotent stem cells (hiPSC)-derived cardiomyocytes. We present a method to analyze contraction force and exemplary alteration of contraction pattern by the hERG channel inhibitor E-4031. This method shows high level of robustness and suitability for cardiac drug screening.
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
0 Views •
Cited by 4 •
2016
Methods to evaluate the efficacy and toxicity of RNA molecules targeting post-integration steps of the HIV-1 replication cycle are described. These methods are useful for screening new molecules and optimizing the format of existing ones.
FAQs
Dose and exposure are central variables because increasing the amount of medicine or the body’s exposure to it can affect both therapeutic response and harmful outcomes. Researchers therefore examine how responses change across dosing conditions rather than evaluating a medicine at a single level. These findings support selection of doses that provide meaningful benefit while limiting unacceptable risk.
Pharmacokinetics describes drug exposure in the body, while pharmacodynamics examines how that exposure produces effects. Considering both helps researchers connect a selected dose with the intended response and with possible adverse effects. This pharmacological relationship informs dose selection, interpretation of clinical findings, and patient monitoring when exposure or response may vary.
Adverse effects can change the acceptability of a treatment even when it produces the desired response. Interactions with other substances may also alter exposure, pharmacological effects, or the likelihood of harm. Evaluating these factors together helps characterize the conditions under which a medicine remains suitable and supports more informed prescribing and monitoring decisions.
These stages provide complementary evidence across drug development. Preclinical studies begin the evaluation before routine human use, clinical trials assess therapeutic effects and harmful outcomes in studied populations, and post-marketing surveillance continues observation after wider use. Together, they expand the evidence needed to establish a medicine’s benefit-risk profile and identify safety information that may emerge later.
A benefit-risk profile brings evidence about therapeutic effects and harmful outcomes into a single decision framework. It helps determine whether the observed benefits justify the identified risks under particular dosing and use conditions. Regulatory decisions and development plans can then reflect the overall balance rather than relying on efficacy or safety findings in isolation.
Findings from pharmacological and clinical evaluation inform appropriate dosing, prescribing practices, and follow-up. Clinicians and researchers can use them to consider exposure, pharmacodynamic response, adverse effects, and interactions when assessing treatment. Continued monitoring helps identify whether the medicine is delivering meaningful benefit and whether emerging harms require attention during use.